News & Comment

Two years after the biotech industry was called out on gender imbalance, the lack of racial diversity in the workforce is largely being ignored.

Regulators, scientists and surgeons are preparing the groundwork for human trials of engineered pig organs—and industry is starting to take notice.

Is it time to reassess the 14-day rule for human embryo research?

The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.

Investment is skewing early as venture capitalists grapple with a volatile political environment, a hot stock market and a flagging IPO outlook.

Our annual survey highlights several academic startups developing immunotherapies as well as ventures focusing on microbiomes, proteostasis, integrin biology, nucleic acid delivery and subcellular imaging.